Chemical Property of Alcaftadine
Chemical Property:
- Melting Point:167 °C
- Boiling Point:556.2±60.0 °C(Predicted)
- PKA:8.76±0.20(Predicted)
- PSA：38.13000
- Density:1.24
- LogP:2.71710
- Storage Temp.:Inert atmosphere,Store in freezer, under -20°C
- XLogP3:1.7
- Hydrogen Bond Donor Count:0
- Hydrogen Bond Acceptor Count:3
- Rotatable Bond Count:1
- Exact Mass:307.168462302
- Heavy Atom Count:23
- Complexity:479
- Purity/Quality:
-
99%, *data from raw suppliers
Alcaftadine *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1
- Recent ClinicalTrials:Safety and Efficacy Study of a Eye Drop for Eye Allergy
-
Description
Alcaftadine, a histamine H1/H2 receptor antagonist, was approved in
the United States in 2010 for the prevention of itching and redness associated
with allergic conjunctivitis. Seasonal and perennial allergic conjunctivitis
affects up to 40% of the population worldwide. There are
numerous treatment options, with topical antihistamines being an effective
therapy. Some of the primary symptoms and signs of allergic conjunctivitis
are ocular itching and conjunctival redness. The pharmaceutical
market for conjunctivitis is substantial and steadily increasing.
-
Uses
Alcaftadine is a H1 histamine receptor antagonist. Alcaftadine is used to prevent eye irritation and treat the signs and symptoms of allergic conjunctivitis.
-
Clinical Use
Alcaftadine, an ophthalmic histamine H1 receptor antagonist,
was approved by the FDA for the prevention of itching associated
with allergic conjunctivitis and was launched under the trade
name Lastacaft in early 2011. Alcaftadine was discovered by
Janssen Pharmaceuticals and marketed by Vistakon Pharmaceuticals,
both subsidiaries of Johnson & Johnson. However, unlike other marketed drugs, the synthesis of alcaftadine was only mentioned
in the patents filed by Janssen’s scientists approximately twenty
years ago.
